Israel’s pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion, a compound annual growth rate of 2.8%, by 2020, says UK research and consulting firm GlobalData.
Israel’s pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion, a compound annual growth rate of 2.8%, by 2020, says UK research and consulting firm GlobalData. This modest growth will driven by “medical technology advances, high R&D expenditure and a robust economy”.The country’s pharmaceutical exports were worth approximately $7.1 billion in 2013, more than four times the value of its imports, which was just over $1.7 billion. Pharmaceuticals represent the largest and most established sector of the Israeli life science industry, with a total of 76 companies, 22% of which are involved in drug discovery and 17% in drug delivery, said Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics.
The country also has a highly skilled population; it is ranked second in the world for percentage of engineers and scientists in the workforce. Owide adds: “Approximately 24% of Israel’s workers hold university degrees, placing it third among the industrialized countries, after the US and Netherlands.”
Johnson and Johnson’s Doxil for ovarian cancer was originally developed at the Hadassah Medical Center, and Novartis’ Exelon, for Alzheimer’s disease, originated from research conducted at the Hebrew University.
Source: GlobalData
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.